エーザイ、11名の先端医療機関の専門家および8名のエーザイ研究者による「レカネマブ」の早期アルツハイマー病に対する臨床第III相Clarity AD検証試験結果の論文がthe New England Journal of Medicineに掲載 Eisai Nov 30, 2022 17:30 JST Read More
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference Eisai Nov 30, 2022 09:21 HKT/SGT Read More
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine Eisai Nov 30, 2022 08:31 HKT/SGT Read More
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Eisai Nov 29, 2022 18:28 HKT/SGT Read More
Tianda Pharma Announces 2022/23 Interim Results Tianda Pharmaceuticals Limited Nov 25, 2022 23:54 HKT/SGT Read More
JBM Healthcare Announces FY2023 Interim Results JBM (Healthcare) Limited Nov 25, 2022 23:25 HKT/SGT Read More
Jacobson Pharma Announces FY2023 Interim Results Jacobson Pharma Corporation Limited Nov 25, 2022 21:21 HKT/SGT Read More
EC Healthcare Announces FY2022/23 Interim Results, Revenue Increased 31.1% YoY Mainly Driven by Medical Services EC Healthcare Nov 24, 2022 13:02 HKT/SGT Read More
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting Eisai Nov 24, 2022 08:04 HKT/SGT Read More
Malaysian Genomics Sees Rise in Profit Margins for 1Q Malaysian Genomics Resource Centre Bhd Nov 23, 2022 17:30 HKT/SGT Read More